Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
186.73B
Market cap186.73B
Price-Earnings ratio
10.23
Price-Earnings ratio10.23
Dividend yield
3.03%
Dividend yield3.03%
Average volume
13.82M
Average volume13.82M
High today
$41.80
High today$41.80
Low today
$40.59
Low today$40.59
Open price
$40.94
Open price$40.94
Volume
11.70M
Volume11.70M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

Benzinga 5h
Novo Nordisk Scores EU Win For Hemophilia Drug, Advances Sickle Cell Treatment Toward Approval

Novo Nordisk (NYSE:NVO) announced on Friday that European regulators approved its hemophilia A therapy, Frehemgo, while the company filed U.S. and European mark...

Novo Nordisk Scores EU Win For Hemophilia Drug, Advances Sickle Cell Treatment Toward Approval
TipRanks 7h
Cboe data shows mixed options sentiment in Novo Nordisk with shares up 0.65%

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares up 26c, or 0.65%, near $40.91. Options volume relatively light with 6070 contracts tr...

The Wall Street Journal 11h
Health Care Roundup: Market Talk

george frey / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk

Analyst ratings

50%

of 8 ratings
Buy
25%
Hold
50%
Sell
25%

More NVO News

The Motley Fool 2d
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?

Novo Nordisk (NVO +0.96%) received a vote of confidence from JPMorgan Chase's (JPM +0.39%) analyst ahead of the drug maker's earnings report. The analyst was ex...

JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
Simply Wall St 2d
Novo Nordisk Stock May Trade Below Fair Value Following Raised Outlook

has seen a sharp reset in its share price over the past few years, even as it remains in the spotlight for obesity and diabetes treatments. With the stock now a...

Novo Nordisk Stock May Trade Below Fair Value Following Raised Outlook
24/7 Wall St. 2d
Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady
24/7 Wall St. 3d
Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady
The Motley Fool 3d
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?

Eli Lilly (LLY +0.54%) and Novo Nordisk (NVO -1.97%) are leading drugmakers in the highly lucrative GLP-1 market, where demand is through the roof for weight lo...

Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?
MarketWatch 4d
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss

The U.S. will now require companies that sell GLP-1 medications like Ozempic and Zepbound to include a warning about the possible risk of vision loss. Several...

Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
The Motley Fool 4d
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.

Eli Lilly (LLY -0.79%) and Novo Nordisk (NVO +0.03%) both participate in one of the biggest pharma growth markets today, and that's the weight loss drug market....

Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.